121 related articles for article (PubMed ID: 16381664)
1. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments.
Ballent M; Lifschitz A; Virkel G; Sallovitz J; Lanusse C
Drug Metab Dispos; 2006 Mar; 34(3):457-63. PubMed ID: 16381664
[TBL] [Abstract][Full Text] [Related]
2. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: P-glycoprotein involvement and itraconazole modulation.
Lifschitz A; Ballent M; Virkel G; Sallovitz J; Lanusse C
J Pharm Pharmacol; 2006 Aug; 58(8):1055-62. PubMed ID: 16872551
[TBL] [Abstract][Full Text] [Related]
3. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition.
Ballent M; Lifschitz A; Virkel G; Sallovitz J; Lanusse C
J Vet Pharmacol Ther; 2007 Jun; 30(3):242-8. PubMed ID: 17472656
[TBL] [Abstract][Full Text] [Related]
4. Loperamide modifies the tissue disposition kinetics of ivermectin in rats.
Lifschitz AL; Virkel GL; Sallovitz JM; Pis A; Imperiale FA; Lanusse CE
J Pharm Pharmacol; 2004 Jan; 56(1):61-7. PubMed ID: 14980002
[TBL] [Abstract][Full Text] [Related]
5. Combined use of ivermectin and triclabendazole in sheep: in vitro and in vivo characterisation of their pharmacological interaction.
Lifschitz A; Virkel G; Ballent M; Sallovitz J; Lanusse C
Vet J; 2009 Nov; 182(2):261-8. PubMed ID: 18640064
[TBL] [Abstract][Full Text] [Related]
6. Gender-related differences on P-glycoprotein-mediated drug intestinal transport in rats.
Mariana B; Adrián L; Guillermo V; Juan S; Laura M; Carlos L
J Pharm Pharmacol; 2011 May; 63(5):619-26. PubMed ID: 21492163
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition.
Ballent M; Lifschitz A; Virkel G; Mate L; Lanusse C
J Vet Pharmacol Ther; 2010 Jun; 33(3):252-9. PubMed ID: 20557442
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus.
Bartley DJ; McAllister H; Bartley Y; Dupuy J; Ménez C; Alvinerie M; Jackson F; Lespine A
Parasitology; 2009 Aug; 136(9):1081-8. PubMed ID: 19549355
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs.
Alvarez L; Lifschitz A; Entrocasso C; Manazza J; Mottier L; Borda B; Virkel G; Lanusse C
J Vet Pharmacol Ther; 2008 Jun; 31(3):230-9. PubMed ID: 18471144
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ivermectin against Strongyloides stercoralis infection in jirds (Meriones unguiculatus).
Sithithaworn P; Fujimaki Y; Mitsui Y; Prasanthong R; Yutanawiboonchai W; Aoki Y
Exp Parasitol; 1998 Jun; 89(2):205-12. PubMed ID: 9635444
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin (3.15%) long-acting formulations in cattle: absorption pattern and pharmacokinetic considerations.
Lifschitz A; Virkel G; Ballent M; Sallovitz J; Imperiale F; Pis A; Lanusse C
Vet Parasitol; 2007 Jul; 147(3-4):303-10. PubMed ID: 17524559
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice.
Kiki-Mvouaka S; Ménez C; Borin C; Lyazrhi F; Foucaud-Vignault M; Dupuy J; Collet X; Alvinerie M; Lespine A
Drug Metab Dispos; 2010 Apr; 38(4):573-80. PubMed ID: 20089736
[TBL] [Abstract][Full Text] [Related]
13. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
[TBL] [Abstract][Full Text] [Related]
14. Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds.
Moreno L; Ceballos L; Lifschitz A; Bistoletti M; Alvarez L; Lanusse C
Res Vet Sci; 2010 Apr; 88(2):315-20. PubMed ID: 19892381
[TBL] [Abstract][Full Text] [Related]
15. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs.
Arellano C; Philibert C; Vachoux C; Woodley J; Houin G
J Pharm Pharm Sci; 2007; 10(1):26-36. PubMed ID: 17498391
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the p-glycoproein-mediated intestinal secretion of glibenclamide: in vitro and in vivo assessments.
Srirangam P; Vidya SJ
J Young Pharm; 2010 Oct; 2(4):379-83. PubMed ID: 21264098
[TBL] [Abstract][Full Text] [Related]
17. Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo.
Shirasaka Y; Masaoka Y; Kataoka M; Sakuma S; Yamashita S
Drug Metab Dispos; 2008 May; 36(5):916-22. PubMed ID: 18276834
[TBL] [Abstract][Full Text] [Related]
18. Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats.
Gokbulut C; Bilgili A; Hanedan B; Aksit D; Aksoy AM; Turgut C
Res Vet Sci; 2009 Dec; 87(3):445-8. PubMed ID: 19410269
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
20. Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs.
Pérez R; Palma C; Cabezas I; Araneda M; Rubilar L; Alvinerie M
J Vet Med A Physiol Pathol Clin Med; 2006 Feb; 53(1):43-8. PubMed ID: 16411909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
